Home
About Us
Company Overview
Mission
Leadship
Milestones
Science
Technology Platforms
Research Areas
Pipeline
Partnerships
News
News
Contact Us
EN
中文
EN
Home
About Us
Science
Technology Platforms
Research Areas
Pipeline
Partnerships
News
News
Contact Us
新闻中心
公司新闻
2025-10
2025
Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism
2025-10-20
2025-10
2025
Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China
2025-10-20
2025-10
2025
Sciwind Biosciences Announces Positive Results from Phase 1 Clinical Trial of XW004, an Oral Formulation of Long-acting GLP-1 Analog Ecnoglutide
2025-10-20
2025-10
2025
Sciwind Biosciences and HK inno.N Corporation Announce Licensing and Partnership Agreement for Ecnoglutide Injection (XW003) in South Korea
2025-10-20
2025-10
2025
Marketing Authorization Application for Ecnoglutide, a First-in-Class Biased GLP-1 Peptide Agonist, has Been Accepted by the NMPA of China
2025-10-20
2025-10
2025
Sciwind’s Second Marketing Authorization Application of Ecnoglutide for Chronic Weight Management Has Been Accepted by the NMPA of China
2025-10-20
2025-10
2025
Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio
2025-10-20
2025-10
2025
Sciwind Biosciences to Present Phase 3 Clinical Data on Ecnoglutide (GLP-1 analog) for Obesity and Type 2 Diabetes, and Preclinical Data on Novel Urocortin 2 Analog at ADA2025
2025-10-17
2025-10
2025
Sciwind Biosciences Announces Publication of Phase III SLIMMER Trial Results in The Lancet Diabetes & Endocrinology and Oral Presentation at ADA Scientific Sessions
2025-10-17
2025-10
2025
Sciwind Biosciences Published T2DM Phase III EECOH-2 Trial Results of Ecnoglutide in Lancet Diabetes & Endocrinology
2025-10-17
<
1
2
3
4
>
